A 54-year-old male on chronic hemodialysis, who was taking rifampicin for tuberculous lymphadenitis, was admitted for an acute gout attack. After administrating 3.6 mg of colchicine for 2 days, symptoms began to alleviate. Despite the relatively high dosage in this end-stage renal disease patient, there were no adverse effects, such as diarrhea, vomiting, or myopathy. After 1 and 6 hours of 0.6 mg colchicine administration, serum colchicine was 1.3930 ng/mL and 0.2464 ng/mL, respectively. These values were lower than the mean concentrations in 13 other patients with chronic kidney disease (CKD) after the same time intervals (4.34±0.56 ng/mL and 1.49±0.15 ng/mL, respectively). As rifampicin is an inducer of cytochrome P450 3A4, metabolism of colchicine had increased. When taking colchicine and rifampicin simultaneously, a higher colchicine dose may be needed for the treatment of acute gout in patients with CKD.
Introduction
Both the incidence and the prevalence of gout are increasing worldwide due to dietary behavior and lifestyle changes.
Nevertheless, the treatment for gout remains insufficient. For acute gouty arthritis, the frontline recommended drugs are non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid, alone or in combination, in patients with normal kidney function (1) . Since NSAIDs can impair kidney function, they have generally been avoided for the treatment of acute gout in patients with chronic kidney disease (CKD). Colchicine or steroids have been the treatment of choice for acute gout in patients with CKD.
A relatively low colchicine dose can affect gout in patients with normal renal function (1,2). The recommended colchicine dosage is 1.2 mg, followed 1 hour later by a further 0.6 mg for the treatment of acute gout in patients with normal renal function (2) . However, in patients with CKD, no guidelines have been set by clinical trials, although the recommended colchicine dosage should be lowered.
Here, we report a patient with CKD who displayed no effects for pain and no adverse effects despite a relatively high colchicine dose. To determine the cause, we measured the colchicine concentration in 13 other patients with CKD.
Case Report
A 54-year-old male was admitted to the hospital for evaluation of severe pain in both ankles, metatarsal joint, big toe, and knees. He had end-stage renal disease (ESRD) due to focal segmental glomerulosclerosis and been on chronic hemodialysis therapy. He has been medicated with isoniazid, ethambutol, and rifampicin for the treatment of tuberculous lymphadenitis for 2 weeks before the start of the pain. On admission, physical examination revealed a blood pressure of 120/68 mmHg, body temperature of 36.9 o C, respiration rate of 20/min, and pulse rate of 78/min. The daily urine output was 300 mL. The review of systems was unremarkable except for multiple joint pain. On physical examinations, both knees, ankles and metatarsal joints evidenced swelling, tenderness and local heat. Laboratory results showed high serum uric acid and impaired kidney function on admission and discharge (Table 1 ). There were no bacteria in the joint fluid and no growth in cultures of joint fluid. Monosodium urate crystals were evident in the right knee joint fluid. Therefore, he was diagnosed with an acute attack of gout arthritis.
Given the active tuberculosis, we could not use steroids. On the first day, we prescribed a lower dosage of colchicine according to the established guideline. There was no symptom relief. After daily administration of colchicine 1.8 mg for 9 days, there was still no improvement of pain, although there was no adverse effect of colchicine. The colchicine dose was then doubled to 3.6 mg daily. After 2 days of 3.6 mg colchicine administration, the pain began to be relieved. The level of high-sensitivity C reactive protein (CRP) was decreased after taking higher colchicine dose. On day 11 of admission, the level of CRP was decreased from 16.5 to 4.7 mg/dL. 
Discussion

Summary
When taking colchicine and rifampicin simultaneously, a high colchicine dose is needed to treat acute gout in patients with CKD.
